Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 7

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 7
---
 assess the safety profile of
our compound and characterization of the drug metabolism. We have conducted several metabolism studies designed to better understand
the way 5-Methoxy-2-aminoindane, or MEAI, is digested in several species. In addition, we have conducted a pre-clinical animal model
of AUD to characterize the effect of MEAI on alcohol consumption. This study involved testing the effect of MEAI’s ability to curb
alcohol cravings after exposing mice to prolonged alcohol consumption over a short period, mimicking binge alcohol consumption in humans.

In February 2024 and in July 2024, we announced
that we were granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate our first-in-human Phase I/IIa
clinical trial with CMND-100 in patients suffering from AUD. Subsequently, in May 2023 we initiated the CM-CMND-001 clinical trial in
both Israel and the United States, including at the Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University
School of Medicine. In October 2024 and December, we announced that we received IRB approvals from Johns Hopkins University and Yale
University, respectively, our clinical sites for part A of our Phase I/IIa clinical trial in the United States for treating patients
suffering from AUD.

The CM-CMND-001 clinical trial is designed
to be a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic study
in healthy volunteers and AUD subjects. Upon completion of the Phase I/IIa studies, if successful, we will be required to conduct additional
clinical trials subject to securing additional financing.

About MEAI

MEAI is a synthetic molecule. Its mechanism of
action has been studied and published in past scientific papers. It was found to interact with the serotonergic receptors 5-HT1A and
5-HT2B and the adrenergic receptors α2A, α2B and α2C receptors. Studies conducted in animals and humans have demonstrated
the role of 5-HT1A receptors in alcohol-drinking behavior. Several 5-HT1A receptor agonists have been tested in animal models to demonstrate
the role of this receptor in alcohol dependence. These preclinical studies suggest that 5-HT1A receptor agonists may play a role in reducing
alcohol intake. In addition, evidence suggests that α2-adrenerg